Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1978-1987

  Martello, Laura A ^a   McDaid, Hayley M ^a   Regl, Donna Lee ^a   Yang, Chia Ping H ^a   Meng, Dongfang ^b   Pettus, Thomas R R ^b   Kaufman, Michael D ^c   Arimoto, Hirokazu ^c   Danishefsky, Samuel J ^b   Smith III, Amos B ^c   Horwitz, Susan Band ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISCODERMOLIDE; ELEUTHEROBIN; EPOTHILONE B; PACLITAXEL;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL CYCLE; CELL DIVISION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MICROTUBULE; PRIORITY JOURNAL;

ALKALOIDS; ALKANES; ANIMALS; ANTINEOPLASTIC AGENTS; CARBAMATES; CELL COUNT; CELL DIVISION; CELL LINE; CYTOSKELETON; DITERPENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EPOTHILONES; EPOXY COMPOUNDS; FLOW CYTOMETRY; HUMANS; LACTONES; LUNG NEOPLASMS; MICROTUBULES; MITOSIS; P-GLYCOPROTEINS; PACLITAXEL; PYRONES; THIAZOLES; TUMOR CELLS, CULTURED;

EID: 18844469806     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Schiff, P. B., Fant, J., and Horwitz, S. B. Promotion of microtubule assembly in vitro by Taxol. Nature (Lond.), 277: 665-667, 1979.
2. Rowinsky, E. K., and Donehower, R. C. Paclitaxel (Taxol). N. Engl. J. Med., 332: 1004-1014, 1995.
3. Rao, S., Krauss, N. E., Heerding, J. M., Swindell, C. S., Ringel, I., Orr, G. A., and Horwitz, S. B. 3′-(p-Azidobenzamido)Taxol photolabels the N-terminal 31 amino acids of β-tubulin. J. Biol. Chem., 269: 3132-3134, 1994.
4. Rao, S., Orr, G. A., Chaudhary, A. G., Kingston, D. G., and Horwitz, S. B. Characterization of the Taxol binding site on the microtubule. 2-(m-Azidobenzoyl)Taxol photolabels a peptide (amino acids 217-231) of β-tubulin. J. Biol. Chem., 270: 20235-20238, 1995.
5. Schiff, P. B., and Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA, 77: 1561-1565, 1980.
6. Jordan, M. A., Toso, R. J., Thrower, D., and Wilson, L. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations. Proc. Natl. Acad. Sci. USA, 90: 9552-9556, 1993.
7. Jordan, M. A., Wendell, K., Gardiner, S., Deny, W. B., Copp, H., and Wilson, L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res., 56: 816-825, 1996.
8. Torres, K., and Horwitz, S. B. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res., 58: 3620-3626, 1998.
9. Gottesman, M. M., and Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem., 62: 385-427, 1993.
10. Ter Haar, E., Kowalski, R. J., Hamel, E., Lin, C. M., Longley, R. E., Gunasekera, S. P., Rosenkranz, H. S., and Day, B. W. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than Taxol. Biochemistry, 35: 243-250, 1996.
11. Hung, D. T., Chen, J., and Schreiber, S. L. (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks Taxol binding and results in mitotic arrest. Chem. Biol., 3: 287-293, 1996.
12. Kowalski, R. J., Giannakakou, P., Gunasekera, S. P., Longley, R. E., Day, B. W., and Hamel, E. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol. Pharmacol., 52: 613-622, 1997.
13. Balachandran, R., Ter Haar, E., Welsh, M. J., Grant, S. G., and Day, B. W. The potent microtubule-stabilizing agent (+)-discodermolide induces apoptosis in human breast carcinoma cells: preliminary comparisons to paclitaxel. Anti-Cancer Drugs, 9: 67-76, 1998.
14. Bollag, D. M., McQueney, P. A., Zhu, J., Hensens, O., Koupal, L., Liesch, J., Goetz, M., Lazarides, E., and Woods, C. M. Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action. Cancer Res., 55: 2325-2333, 1995.
15. Kowalski, R. J., Giannakakou, P., and Hamel, E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol). J. Biol. Chem., 272: 2534-2541, 1997.
16. Mann, J. Myxobacterial bounty. Nature (Lond.), 385: 117, 1997.
17. Su, D-S., Balog, A., Meng, D., Bertinato, P., Danishefsky, S. J., Zheng, Y-H., Chou, T-C., He, L., and Horwitz, S. B. Structure-activity relationships of the epothilones and the first in vivo comparison with paclitaxel. Agnew. Chem. Int. Ed. Engl., 36: 2093-2096, 1997.
18. Lindel, T., Jensen, P. R., Fenical, W., Long, B. H., Casazza, A. M., Carboni, J., and Fairchild, C. R. Eleutherobin, a new cytotoxin that mimics paclitaxel (Taxol) by stabilizing microtubules. J. Am. Chem. Soc., 119: 8744-8745, 1997.
19. McDaid, H. M., Bhattacharya, S. K., Chen, X-T., He, L., Shen, H-J., Gutteridge, C. E., Horwitz, S. B., and Danishefsky, S. J. Structure-activity profiles of eleutherobin analogs and their cross-resistance in Taxol-resistant cell lines. Cancer Chemother. Pharmacol., 44: 131-137, 1999.
20. Long, B. H., Carboni, J. M., Wasserman, A. J., Cornell, L. A., Casazza, A. M., Jensen, P. R., Lindel, T., Fenical, W., and Fairchild, C. R. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol). Cancer Res., 58: 1111-1115, 1998.
21. Rowinsky, E. K., Gilbert, M. R., McGuire, W. P., Noe, D. A., Grochow, L. B., Forastiere, A. A., Ettinger, D. S., Lubejko, B. G., Clark, B., Sartorius, S. E., Cornblath, D. R., Hendricks, C. B., and Donehower, R. C. Sequences of Taxol and cisplatin: a Phase I and pharmacologic study. J. Clin. Oncol., 9: 1692-1703, 1991.
22. Goldspiel, B. R. Clinical overview of the taxanes. Pharmacotherapy, 17: 110S-125S, 1997.
23. Amadori, D., Frassineti, G. L., Zoli, W., Milandri, C., Tienghi, A., Ravaioli, A., Gentile, A., and Salzano, E. A Phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer. Semin. Oncol., 23: 16-22, 1996.
24. Klaassen, U., Wilke, H., Harstrick, A., Philippou Pan, C., Strumberg, D., Neumann, K., Eberhardt, W., Achterrath, W., Lenaz, L., and Seeber, S. Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: results of a Phase II study. Ann. Oncol., 9: 45-50, 1998.
25. Felip, E., Massuti, B., Camps, C., Benito, D., Isla, D., Gonzalez-Larriba, J. L., Lopez-Cabrerizo, M. P., Salamanca, O., Puerto-Pica, J., Moyano, A., Baselga, J., and Rosell, R. Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer: comparison of two Phase II trials. Clin. Cancer Res., 4: 2723-2728, 1998.
26. McDaid, H. M., and Johnston, P. G. Synergistic interaction between paclitaxel and 8-chloro-adenosine 3′,5′-monophosphate in human ovarian carcinoma cell lines. Clin. Cancer Res., 5: 215-220, 1999.
27. Tortoriello, A., Facchini, G., Caponigro, F., Santangelo, M., Benassai, G., Persico, G., Citarella, A., Carola, M., Marzano, N., and Iaffaioli, R. V. Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer. Breast Cancer Res. Treat., 47: 91-97, 1998.
28. Keren-Rosenberg, S., and Muggia, F. M. Response to estramustine phosphate and paclitaxel in patients with advanced breast cancer: a Phase I study. Semin. Oncol., 24: S26-S29, 1997.
29. Hudes, G. R., Nathan, F., Khater, C., Haas, N., Cornfield, M., Giantonio, B., Greenberg, R., Gomella, L., Litwin, S., Ross, E., Roethke, S., and McAleer C. Phase II trial of 96- hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J. Clin. Oncol., 15: 3156-3163, 1997.
30. Kavallaris, M., Kuo, D. Y-S., Burkhart, C. A., Regl, D. L., Norris, M. D., Haber, M., and Horwitz, S. B. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J. Clin. Investig., 100: 1282-1293, 1997.
31. Balog, A., Meng, D., Kamenecka, T., Bertinato, P., Su, D-S., Sorensen, E. J., and Danishefsky, S. J. Total synthesis of (-)-epothilone A. Agnew. Chem. Int. Ed. Engl., 35: 2801-2803, 1996.
32. Su, D-S., Meng, D., Bertinato, P., Balog, A., Sorensen, E. J., Danishefsky, S. J., Zheng, Y-H., Chou, T-C., He, L., and Horwitz, S. B. Total synthesis of (-)-epothilone B: an extension of the Suzuki coupling method and insights into structure-activity relationships of the epothilones. Agnew. Chem. Int. Ed. Engl., 36: 757-759, 1997.
33. Meng, D., Bertinato, P., Balog, A., Su, D-S., Kamencka T., Sorensen, E., and Danishefsky, S. J. The total syntheses of epothilones A and B. J. Am. Chem. Soc., 119: 10073-10092, 1997.
34. Chen, X-T., Zhou, B., Bhattacharya, S. K., Gutteridge, C. E., Pettus, T. R. R., and Danishefsky, S. J. The total synthesis of eleutherobin: a surprise ending. Agnew. Chem. Int. Ed. Engl., 37: 789-792, 1998.
35. Smith, A. B., III, Kaufman, M. D., Beauchamp, T. J., LaMarche, M. J., and Arimoto, H. Gram-scale synthesis of (+)-discodermolide. Org. Lett., I: 1823-1826, 1999.
36. Haber, M., Burkhart, C. A., Regl, D. L., Madafiglio, J., Norris, M. D., and Horwitz, S. B. Altered expression of Mβ2, the class II β-tubulin isotype, in a murine J774.2 cell line with a high level of Taxol resistance. J. Biol. Chem., 270: 31269-31275, 1995.
37. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
38. Ojima, I., Chakravarty, S., Inoue, T., Lin, S., He, L., Horwitz, S. B., Kuduk, S. D., and Danishefsky, S. J. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc. Natl. Acad. Sci. USA, 96: 4256-4261, 1999.
39. Cabral, F. R., Wible, L., Brenner, S., and Brinkley, B. R. Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J. Cell Biol., 97: 30-39, 1983.
40. Hyams, J. S., and Lloyd, C. W. (eds.). Microtubules. New York: Wiley-Liss, Inc., 1994.
41. Giannakakou, P., Villalba, L., Li, H., Poruchynsky, M., and Fojo, T. Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule. Int. J. Cancer, 75: 57-63, 1998.
42. Giannakakou, P., Sackett, D. L., Nogales, E., Downing, K. H., and Fojo, T. A β-tubulin mutation confers epothilone resistance in human cancer cells. Proc. Am. Assoc. Cancer Res., 40: 1885, 1999.
43. Longley, R. E., Gunasekera, S. P., Faherty, D., Mclane, J., and Dumont, F. Immunosuppression by discodermolide. Ann. N. Y. Acad. Sci., 696: 94-107, 1993.
44. Haux, J., Johnsen, A. C., Steinkjer, B., Egeberg, K., Sundan, A., and Espevik, T. The role of interleukin-2 in regulating the sensitivity of natural killer cells for Fas-mediated apoptosis. Cancer Immunol. Immunother., 48: 139-146, 1999.